Difference between revisions of "Cefixime"

From Self-sufficiency
Jump to: navigation, search
(→‎In India)
 
m (1 revision: World Health Organization essential medicines)
 
(2 intermediate revisions by 2 users not shown)
Line 29: Line 29:
 
The usual dose is 400 mg in two divided doses for up to 5-7 days.
 
The usual dose is 400 mg in two divided doses for up to 5-7 days.
  
−
It was sold under the trade name '''Suprax''' in the USA, until 2003 when it was taken off the market by drug manufacturer [[Wyeth]] after its [[patent]] expired. The oral suspension form of "Suprax" was re-launched by Lupin in the USA. It is available under the Brand Name '''Kafixim''' in India and is manufactured and marketed by '''Kaptab Pharmaceuticals'''. Cefixime is available in Pakistan under trade name '''Waybac''' and in Spain as "Denvar" (cefixime is known as cefixima). Cefixime is still available in [[Canada]].
+
It was sold under the trade name '''Suprax''' in the USA, until 2003 when it was taken off the market by drug manufacturer [[Wyeth]] after its [[patent]] expired. The oral suspension form of "Suprax" was re-launched by Lupin in the USA.  
−
Cefixime also has huge sales in Indian subcontinent and middle east.
+
  
−
==Sold with brand names==
 
−
===In India===
 
−
* Ziprax
 
−
* Zofix
 
−
* Lafix
 
  
 
==References==
 
==References==

Latest revision as of 15:52, 27 September 2010

Cefixime
File:Cefixime.svg
Systematic (IUPAC) name
(6R,7R)-7-{[2-(2-amino-1,3-thiazol-4-yl)-2-(carboxy
methoxyimino)acetyl]amino}-3-ethenyl-8-oxo-5-thia-
1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Clinical data
Pregnancy
category
  • B
Routes of
administration		 Oral
Pharmacokinetic data
Bioavailability 40% to 50%
Protein binding Approximately 60%
Biological half-life Variable
Average 3 to 4 hours
Excretion Renal and biliary
Identifiers
CAS Number 79350-37-1
ATC code J01DD08 (WHO)
PubChem CID 5362065
DrugBank APRD00583
ChemSpider 4514923
Chemical data
Formula C16H15N5O7S2
Molar mass 453.452 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
  (verify)
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Cefixime is an oral third generation cephalosporin antibiotic. It is used to treat gonorrhea,[1] tonsilitis,[2] and pharyngitis.[2]

The usual dose is 400 mg in two divided doses for up to 5-7 days.

It was sold under the trade name Suprax in the USA, until 2003 when it was taken off the market by drug manufacturer Wyeth after its patent expired. The oral suspension form of "Suprax" was re-launched by Lupin in the USA.


References

  1. ↑ McMillan A, Young H. (2007). "The treatment of pharyngeal gonorrhoea with a single oral dose of cefixime". Int J STD AIDS. 18 (4): 253–4. doi:10.1258/095646207780658971. PMID 17509176. 
  2. ↑ 2.0 2.1 Adam D, Hostalek U, Tröster K. (1995). "5-day cefixime therapy for bacterial pharyngitis and/or tonsillitis: comparison with 10-day penicillin V therapy". Infection. 23 (Suppl 2): S83–6. doi:10.1007/BF01742990. PMID 8537138. 
Intracellular
inhibit peptidoglycan subunit synthesis and transport: NAM synthesis inhibition (Fosfomycin) · DADAL/AR inhibitors (Cycloserine) · bactoprenol inhibitors (Bacitracin)
Glycopeptide
inhibit PG chain elongation: Vancomycin# (Oritavancin, Telavancin) · Teicoplanin (Dalbavancin) · Ramoplanin
β-lactams/
(inhibit PBP
cross-links)
Combinations
Other

M: BAC

drug(J1p, w, n, m, vacc)

ar:سيفيكزيم

fr:Céfixime it:Cefixima pl:Cefiksym pt:Cefixima th:เซฟิกซิม

Retrieved from "http://ssf.f15ijp.com/wiki/index.php?title=Cefixime&oldid=42696"